- Home
- VOR vs ANIK Comparison
VOR vs ANIK Comparison
Compare VOR & ANIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VOR
- ANIK
- Stock Information
- Founded
- VOR 2015
- ANIK 1983
- Country
- VOR United States
- ANIK United States
- Employees
- VOR N/A
- ANIK N/A
- Industry
- VOR Biotechnology: Pharmaceutical Preparations
- ANIK Medical/Dental Instruments
- Sector
- VOR Health Care
- ANIK Health Care
- Exchange
- VOR Nasdaq
- ANIK Nasdaq
- Market Cap
- VOR 202.4M
- ANIK 196.6M
- IPO Year
- VOR 2021
- ANIK 1993
- Fundamental
- Price
- VOR $2.30
- ANIK $11.45
- Analyst Decision
- VOR Buy
- ANIK Buy
- Analyst Count
- VOR 7
- ANIK 1
- Target Price
- VOR $3.77
- ANIK $19.00
- AVG Volume (30 Days)
- VOR 47.3M
- ANIK 118.5K
- Earning Date
- VOR 08-07-2025
- ANIK 08-07-2025
- Dividend Yield
- VOR N/A
- ANIK N/A
- EPS Growth
- VOR N/A
- ANIK N/A
- EPS
- VOR N/A
- ANIK N/A
- Revenue
- VOR N/A
- ANIK $117,053,000.00
- Revenue This Year
- VOR N/A
- ANIK N/A
- Revenue Next Year
- VOR N/A
- ANIK $9.70
- P/E Ratio
- VOR N/A
- ANIK N/A
- Revenue Growth
- VOR N/A
- ANIK 4.61
- 52 Week Low
- VOR $0.13
- ANIK $10.47
- 52 Week High
- VOR $3.29
- ANIK $29.12
- Technical
- Relative Strength Index (RSI)
- VOR 78.77
- ANIK 50.73
- Support Level
- VOR $2.25
- ANIK $10.91
- Resistance Level
- VOR $3.29
- ANIK $11.47
- Average True Range (ATR)
- VOR 0.52
- ANIK 0.49
- MACD
- VOR 0.18
- ANIK 0.11
- Stochastic Oscillator
- VOR 82.52
- ANIK 83.00
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
About ANIK Anika Therapeutics Inc.
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States and also has its presence in Europe and Other countries.